An annual booster dose of the coronavirus vaccine, which will simultaneously provide protection against influenza and respiratory syncytial virus (RSV), has been announced by Moderna. The radical “three in one” vaccine will be constantly modified for new mutations.
“A pillar of Moderna’s product strategy is the development of an annual commemorative vaccine, which the company plans to continually adapt. The Company believes that it could be the first in the market with a COVID + Influenza + RSV booster vaccine “, it is typically emphasized.
“Even before the Covid-19 pandemic, about three million people died each year from respiratory infections. […] “Our goal is to reduce this weight with an annual booster vaccine,” said Moderna CEO Stefan Bancell.
According to the American Pharmaceutical Company, respiratory infections are the leading cause of death worldwide, with about three million deaths annually. About one million of these deaths occur each year due to respiratory infections in high- and upper-middle-income countries, and respiratory infections are responsible for more deaths from colon cancer in high-income countries. The risk of respiratory virus disease is higher in children under five, adults over 65, and the high-risk population, including pregnant women, the immunocompromised, or cancer patients.
The American pharmaceutical company also announced positive intermediate data from the Phase 1 study of the candidate for the mRNA-1010 vaccine for seasonal flu. The Phase II study has gathered the required number of volunteers, and preparations for the Phase 3 study are ongoing, the company said.
One pillar of our product strategy is to develop a pan-respiratory annual #booster #vaccine, which we plan to continuously customize. We believe that we could be first to market with a COVID + #Flu + #RSV booster vaccine. https://t.co/RXnx5k57hC
– Modern (@moderna_tx) December 10, 2021
Follow Skai.gr on Google News
and be the first to know all the news
.
